# PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Source: https://onco.cc/trials/nct05236972/  
OnCo record `nct05236972` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of sintilimab, fOLFOX (5-FU, leucovorin, oxaliplatin) and capecitabine in colorectal cancer, run by Sun Yat-sen University, now recruiting.

## Summary

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer is a phase 3, randomised interventional study registered as NCT05236972 by Sun Yat-sen University, with a registry enrolment figure of 323 participants, started 2022-01-01 and due to reach its primary completion in 2026-06-01. Interventions recorded: Sintilimab; Oxaliplatin; capecitabine. Conditions listed: Colorectal Carcinoma. Primary outcome: Disease Free survival [ Time Frame: 3 years ]. Colorectal eligibility wording from the registry: ", any T, N1 or N2, M0) adenocarcinoma of the colon (as defined by the presence of the inferior pole of the tumour above the peritoneal reflection - that is, at least 10 cm from the anal margin)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05236972
- Phase: 3
- Setting: Study of Sintilimab vs Standard Therapy in Participants With Mismatch Repair Deficient (dMMR) or Microsatellite Instability-High (MSI-H) Stage III Colorectal Cancer
- Sponsor: Sun Yat-sen University
- Enrolled: 323

## Sources

- ClinicalTrials.gov NCT05236972: https://clinicaltrials.gov/study/NCT05236972

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05236972.json